GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » PB Ratio

Marksans Pharma (NSE:MARKSANS) PB Ratio : 6.41 (As of Dec. 12, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-12), Marksans Pharma's share price is ₹322.75. Marksans Pharma's Book Value per Share for the quarter that ended in Sep. 2024 was ₹50.34. Hence, Marksans Pharma's PB Ratio of today is 6.41.

The historical rank and industry rank for Marksans Pharma's PB Ratio or its related term are showing as below:

NSE:MARKSANS' s PB Ratio Range Over the Past 10 Years
Min: 0.89   Med: 3   Max: 11.64
Current: 6.54

During the past 13 years, Marksans Pharma's highest PB Ratio was 11.64. The lowest was 0.89. And the median was 3.00.

NSE:MARKSANS's PB Ratio is ranked worse than
87.25% of 941 companies
in the Drug Manufacturers industry
Industry Median: 2.09 vs NSE:MARKSANS: 6.54

During the past 12 months, Marksans Pharma's average Book Value Per Share Growth Rate was 19.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 28.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 30.20% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 23.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Marksans Pharma was 69.20% per year. The lowest was -20.00% per year. And the median was 18.55% per year.

Back to Basics: PB Ratio


Marksans Pharma PB Ratio Historical Data

The historical data trend for Marksans Pharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma PB Ratio Chart

Marksans Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 2.31 1.55 1.80 3.33

Marksans Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.62 - 3.33 - 5.92

Competitive Comparison of Marksans Pharma's PB Ratio

For the Drug Manufacturers - General subindustry, Marksans Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marksans Pharma's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's PB Ratio falls into.



Marksans Pharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Marksans Pharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=322.75/50.344
=6.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Marksans Pharma  (NSE:MARKSANS) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Marksans Pharma PB Ratio Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Marksans Pharma Business Description

Traded in Other Exchanges
Address
Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.

Marksans Pharma Headlines

No Headlines